ESP41091, a small molecule, is one of Esperion’s early-stage product candidates.

We are currently exploring ESP41091 in pre-clinical studies and may advance development of the agent as an oral therapy for patients with multiple cardiometabolic risk factors, including Type 2 diabetes and obesity.

In pre-clinical pharmacology studies, oral intervention with ESP41091 resolved hyperglycemia and reduced body weight following a four-week treatment in a diet-induced obese mouse model of insulin resistance. Treatment with ESP41091 also resulted in beneficial effects on lipid metabolism and body weight in obese rats.